48-week outcomes following switch from AZT/3TC to FTC/TDF (TVD) vs. continuing on AZT/3TC: 48-week interim analysis of the RECOMB trial

Ribera, E; Clotet, B; Martínez, E; Estrada, V; Sanz, J; Berenguer, J; Rubio, R; Pulido, F; Larrouse, M; Curran, A; Negredo, E; Ferrer, P; Álvarez, ML

doi:10.1186/1758-2652-11-S1-P54

Journal of the International AIDS Society

Article metrics
Last updated: Thu, 25 Apr 2024 23:39:51 Z

48-week outcomes following switch from AZT/3TC to FTC/TDF (TVD) vs. continuing on AZT/3TC: 48-week interim analysis of the RECOMB trial

Access & Citations

999

Article Accesses
0

Web of Science
2

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.